Status:
TERMINATED
A Study of the Long-term Safety of ABT-089 for Subjects With Mild-to-moderate Alzheimer's Disease Who Participated in the M06-876 Study
Lead Sponsor:
Abbott
Conditions:
Alzheimer's Disease
Eligibility:
All Genders
55-90 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to evaluate the long-term safety and tolerability of ABT-089 in adults with mild-to-moderate Alzheimer's disease.
Eligibility Criteria
Inclusion
- The subject was randomized into Study M06-876 and completed the study.
- The subject must remain on the same dose of AChEI that was used during the M06-876 study.
- The subject is in general good health, as judged by the investigator
Exclusion
- The subject is currently, or plans to participate in another experimental study during the course of this trial.
- The subject anticipates a move outside the geographic area of the investigative site or is planning extended travel inconsistent with the recommended visit intervals.
Key Trial Info
Start Date :
January 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
63 Patients enrolled
Trial Details
Trial ID
NCT00809510
Start Date
January 1 2009
Last Update
September 2 2011
Active Locations (22)
Enter a location and click search to find clinical trials sorted by distance.
1
Site Reference ID/Investigator# 16543
Phoenix, Arizona, United States, 85006
2
Site Reference ID/Investigator# 16528
Sun City, Arizona, United States, 85351
3
Site Reference ID/Investigator# 16524
Fresno, California, United States, 93720
4
Site Reference ID/Investigator# 16520
San Diego, California, United States, 92108